Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYFORM-008
2023-503615-14-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 20
01
Overview
Phase 2, randomised trial of favezelimab + pembrolizumab in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-Free Survival (PFS). Started Aug 2023; status: completed.
02
Drugs
favezelimab + pembrolizumab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2023-503615-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503615-14-00.